Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Yinhuang Inhalation Solution is a traditional Chinese medicine (TCM) formulation developed by Beijing Yingkerei Pharmaceutical Technology for the treatment of respiratory infections. The drug is designed for administration via nebulization, allowing for direct delivery to the respiratory tract. It is based on the traditional Yinhuang preparation, which typically consists of extracts from *Lonicera japonica* (honeysuckle) and *Scutellaria baicalensis* (baicalein). These herbal components are recognized in traditional medicine for their anti-inflammatory, antibacterial, and antiviral properties, primarily attributed to active constituents such as chlorogenic acid and baicalin. By utilizing an inhalation route, the formulation aims to provide localized therapeutic effects in the lungs and airways, potentially offering faster symptom relief for respiratory conditions compared to oral administration. It is currently in the preclinical stage of development.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Yinhuang Inhalation Solution.